Replies to post #259338 on Amarin Corp Plc (AMRN)

[Whalatane]

Rais ...its not in AMRN's control ...until they file and then win the appeal

Teva's settlement in the previous case with AMRN stated they could enter about 6 mths before the patents expired PROVIDED no other generic successfully won a patent battle against AMRN .

Since as of end of business yesterday ..a generic has invalidated Amarins patents ..TEVA can launch as soon as the FDA approves their ANDA .
The only thing that will stop them is "when " AMRN files an appeal ...then Teva's launch will be an " at risk " launch .
Teva already sells a generic version of Lovaza ...already has IMHO a supply chain for generic Vascepa . The only thing stopping them is FDA approval via their ANDA and AMRN filing an appeal ..which would make their launch as I said " at risk "

Thats my understanding of how things are
Kiwi